- Home
- MDXH vs BOLD Comparison
MDXH vs BOLD Comparison
Compare MDXH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- BOLD
- Stock Information
- Founded
- MDXH 2003
- BOLD 2018
- Country
- MDXH Belgium
- BOLD United States
- Employees
- MDXH N/A
- BOLD N/A
- Industry
- MDXH
- BOLD
- Sector
- MDXH
- BOLD
- Exchange
- MDXH Nasdaq
- BOLD Nasdaq
- Market Cap
- MDXH 78.3M
- BOLD 81.0M
- IPO Year
- MDXH 2021
- BOLD 2024
- Fundamental
- Price
- MDXH $2.53
- BOLD $3.59
- Analyst Decision
- MDXH Strong Buy
- BOLD Strong Buy
- Analyst Count
- MDXH 2
- BOLD 3
- Target Price
- MDXH $7.50
- BOLD $23.00
- AVG Volume (30 Days)
- MDXH 44.6K
- BOLD 44.0K
- Earning Date
- MDXH 11-06-2024
- BOLD 11-03-2024
- Dividend Yield
- MDXH N/A
- BOLD N/A
- EPS Growth
- MDXH N/A
- BOLD N/A
- EPS
- MDXH N/A
- BOLD N/A
- Revenue
- MDXH $80,741,000.00
- BOLD N/A
- Revenue This Year
- MDXH $24.45
- BOLD N/A
- Revenue Next Year
- MDXH $15.22
- BOLD N/A
- P/E Ratio
- MDXH N/A
- BOLD N/A
- Revenue Growth
- MDXH 45.51
- BOLD N/A
- 52 Week Low
- MDXH $0.35
- BOLD $2.85
- 52 Week High
- MDXH $4.64
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- MDXH 37.08
- BOLD N/A
- Support Level
- MDXH $2.84
- BOLD N/A
- Resistance Level
- MDXH $2.74
- BOLD N/A
- Average True Range (ATR)
- MDXH 0.12
- BOLD 0.00
- MACD
- MDXH -0.05
- BOLD 0.00
- Stochastic Oscillator
- MDXH 0.00
- BOLD 0.00
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.